Poster

High Viscosity Formulations: Developing A 'Human Solution' To Autoinjector Design

Source: SMC Ltd.

By Jonathan Bradshaw, Oval Medical Technologies

SMC

Within the injectable drug landscape, the availability and use of High Viscosity (HV) formulations is growing, often driven by developments such as Long-Acting Injectable (LAI) technologies. Typically, LAI products consist of formulations that are highly viscous in nature (100cP – 1,000cP) which can present a range of delivery challenges such as non-Newtonian flow, or in the case of suspensions, ‘clogging’ characteristics. Often, these characteristics are well beyond the normal limits of injection devices and can present many difficulties for Subcutaneous (SQ) and Intramuscular (IM) drug delivery. When delivering HV formulations, there exists a delicate balance between achieving safe delivery of the drug and doing so in a way which is practical and acceptable to the patient. However, these requirements often conflict. To create a truly ‘Human Solution’ when delivering HV formulations, a suitable balance between the two must be achieved. This poster discusses the importance of achieving a ‘Human Solution’ to HV autoinjector design.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online